NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer's Trial at AD/PD Conference

Executive Summary

• NetraMark announced that its explainable AI platform, NetraAI, identified two responder subgroups within the Phase 3 A4 anti‑amyloid trial, showing large treatment effects (Cohen’s d up to 1.52) despite the overall trial being negative.
• The findings were presented as a poster at the AD/PD 2026 International Conference in Copenhagen, highlighting the platform’s ability to uncover clinically meaningful patient heterogeneity.
• NetraMark suggests its technology can improve future Alzheimer’s drug development by enabling precision enrichment, retrospective re‑analysis of historic trials, and reduced development risk.

Key Details

• Study Analyzed: Anti‑Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial – Phase 3 solanezumab arm.
• AI Methodology: Dynamical‑systems‑based explainable machine learning using multimodal baseline data (imaging, cognition, demographics, biomarkers).
• Responder Subgroups Identified:
• Subgroup 1 – Higher regional brain volume + stronger baseline cognitive performance; effect size Cohen’s d ≈ 1.52.
• Subgroup 2 – Greater limbic/temporal network integrity (e.g., larger right amygdala or right superior temporal cortex) plus better psychomotor speed and attention scores; similarly large treatment effects.
• Implications Stated:
• Patient heterogeneity can mask drug efficacy in aggregate trial analyses.
• NetraAI can support precision enrichment strategies, improve trial design, enable retrospective insights, and lower development costs/risk.
• Conference Presentation: Poster titled “Decoding Heterogeneity in A4: Explainable ML Identifies Solanezumab‑Responsive Subgroups in Preclinical AD,” presented at AD/PD 2026 International Conference (Mar 17‑21, 2026, Copenhagen).
• Quote from CTO: Dr. Joseph Geraci emphasized that “patient heterogeneity may be masking treatment effects… technologies capable of identifying biologically meaningful responder subgroups could fundamentally reshape how Alzheimer’s clinical trials are designed.”

Notable Quotes

“These findings suggest that patient heterogeneity may be masking treatment effects in Alzheimer’s trials, underscoring the need for approaches such as NetraAI that may identify interpretable patient subpopulations most likely to benefit from emerging therapies,” – Dr. Joseph Geraci, Chief Technical Officer & Founder, NetraMark.